States Dispute Drugmakers’ Bid To Toss GLP-1 Antitrust Case
Wednesday, July 22 – The attorneys general of Texas and Louisiana pushed back on Tuesday against a bid from Novo Nordisk and Eli Lilly to duck a specialty pharmacy’s antitrust case accusing the companies of blocking competition for GLP-1 medications.
Novo’s False Ad Suit Against Eli Lilly Ramps Up GLP-1 Rivalry
Wednesday, July 22 – Pharmaceutical giant Novo Nordisk Inc. slapped rival Eli Lilly & Co. with a false advertising suit in New Jersey federal court Tuesday, calling a marketing campaign for the rival’s weight loss drugs “deceptive” for “withholding critical scientific evidence” about newer GLP-1 formulations.
GLP-1 Maker Sued Over Ads; Vaginal Estrogen; Melinda Gates Talks Perimenopause
Wednesday, July 22 – (MedPage Today) — Novo Nordisk sued rival drugmaker Eli Lilly, alleging false advertising claims about relative weight-loss drug performance. (Reuters via NBC News)
GLP-1 drug use surged from 2017 to 2022, jumping 230% in adults with diabetes…
GLP-1s are linked to a 17% drop in worker sick leave, new study finds
Wednesday, July 22 – Here’s how weight-loss drugs like Ozempic and Wegovy could reduce worker illness and save companies money.
Ozempic maker Novo Nordisk sues US rival over ‘materially misleading’ ads
Wednesday, July 22 – Danish pharma company says Eli Lilly using outdated trial data to make its weight-loss drugs appear more effectiveOzempic maker Novo Nordisk said on Tuesday it is suing arch US rival Eli Lilly over “false and materially misleading” adverts for its competing weight-loss and anti-diabetes treatments.The Danish pharmaceuticals heavyweight complained that the US group – which makes rival weight-loss treatments Zepbound and Mounjaro – “intentionally selected outdated studies” that compared Lilly’s highest doses against lower doses of Novo Nordisk’s medicines. Continue reading…
Ozempic-maker accuses rival of false advertising
Wednesday, July 22 – Novo Nordisk has launched legal action accusing Eli Lilly of creating “misleading” ads, a claim its rival denies.
Novo Nordisk Sues Eli Lilly Over Weight Loss Drug Advertisement
Wednesday, July 22 – Novo Nordisk, which makes Ozempic and Wegovy, has filed a federal lawsuit against Eli Lilly, accusing its competitor of false advertising and unfair competition. Novo Nordisk challenges national ad campaigns from Eli Lilly that compare GLP-1 drugs from both companies, saying that Lilly intentionally relies on outdated clinical trials to paint a false and misleading picture. NBC’s Christine Romans joins TODAY with the details.
STAT+: Novo Nordisk sues Eli Lilly over GLP-1 drug ads it calls ‘deceptive’
Wednesday, July 22 – Novo Nordisk sued Eli Lilly for allegedly running a “deceptive” ad campaign that uses “outdated clinical trials” to make its obesity and diabetes drugs appear more effective.
GLP-1 use rising rapidly among US adolescents and young adults, study finds
Tuesday, July 21 – Adolescents and young adults in the U.S. are increasingly using popular GLP-1 weight-loss drugs alone or in conjunction with metabolic and bariatric surgery (MBS) to manage obesity, according to a study by UT Southwestern Medical Center researchers published in JAMA Pediatrics.
Troubling Findings in Study of GLP-1 Compounders
Tuesday, July 21 – (MedPage Today) — The market for compounded GLP-1 drugs remained robust despite the end of semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) shortages, with many facilities adding ingredients like B vitamins and some operating…